In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Fresenius SE & Co. KGaA

www.fresenius.se

Latest From Fresenius SE & Co. KGaA

Market Intel: Large Providers Focus On Hemodialysis Home Care; New Incentive By Presidential Executive Order

Momentum is rising for patients with chronic kidney disease to be treated with hemodialysis in the comfort of their own home as opposed to traveling several days a week to a freestanding clinic. Manufacturers, government and payers are paving the way for a higher home-therapy adoption rate. That said, many patients remain unsuitable for home care and the large volume of water needed to operate hemodialysis can be logistically daunting.

Market Intelligence Renal

Cara’s Phase III Success In CKD-Pruritus Puts NDA Filing In Sight

Second Phase III study expected later this year, but Cara wants to discuss the possibility of accelerated filing with the US FDA. It also has an oral formulation in Phase II for less severe CKD patients.

Clinical Trials Drug Approval Standards

Dr Reddy’s Management Upbeat Despite Product Delays

Dr Reddy’s had a generally positive Q4 but a slow ramp in some products in the US and potential delays in anticipated launches there are among the challenges that appear to have jaded investor outlook. Management commentary, though, was optimistic, with around 30 launches lined up for the US, a China/India thrust and M&A staying an important cog for growth.

Sales & Earnings Commercial

Product Delays Dull Dr Reddy’s Despite Upbeat Management

Dr Reddy’s had a generally positive Q4 but a slow ramp in some products in the US and potential delays in anticipated launches there are among the challenges that appear to have jaded investor outlook. Management commentary, though, was optimistic, with around 30 launches lined up for the US, a China/India thrust and M&A staying an important cog for growth.

Sales & Earnings Commercial
See All

Company Information

UsernamePublicRestriction

Register